Management

 

Dr. Eran Eden

Co-founder & CEO

Dr. Eden has been the CEO of MeMed since its inception in 2009, leading it from an idea to a rapidly growing company. He has 14 years of combined business and academic experience leading the development of cutting-edge multidisciplinary technologies that synergize molecular biology and informatics. Dr. Eden co-founded several highly funded international consortia (e.g., Tailored-Treatment, Respiratory-ImmunoDx, AutoPilotDx), the mission of which is to develop, clinically validate and commercialize novel technologies for diagnosing patients with infectious diseases and inflammatory disorders. He holds a B.Sc. in Computer Engineering, B.A. in Biology, and M.Sc. in Computer Science (all Cum Laude) from the Technion, Israel Institute of Technology, and a Ph.D. in Systems Biology from the Weizmann Institute of Science. Dr. Eden is co-author of over 20 patents and 20 peer-reviewed publications, and is the recipient of multiple awards including the prestigious GE and Science Prize for Promising Life Scientists

 

Dr. Kfir Oved

Co-Founder, CTO & Chairman of the Board

Dr. Oved co-founded MeMed in 2009 and serves as its CTO and Chairman of the Board. As a bioentrepreneur, he has 15 years of combined industry and academic experience, leading interdisciplinary projects that apply molecular immunology and systems immunology-based technologies to clinical applications. He holds a B.A. in Biology (Summa Cum Laude), B.Sc. in medicine (Magna Cum Laude), Ph.D. in molecular immunology, and 6 years training at the Technion, Israel Institute of Technology Medical school. He served as a scientific advisor at Applied Immune Technologies (acquired by Adicet in 2016) and is the co-author of 83 granted patents and pending applications relating to 20 different patent families. Dr. Oved led development and clinical validation of the MeMed BV™ technology, and also the build of the MeMed Key™ Point of care platform, from conceptualization to development completion. He is the author of 14 peer-reviewed publications, and the recipient of multiple research excellence awards, including the prestigious Wolf Award for research students.

Mr. Idan Danenberg

Chief Operating Officer

Mr. Danenberg has over 15 years of leadership experience in international operations and supply chain, service and lean manufacturing in the pharmaceutical and medical device industries. Before joining MeMed’s team, Mr. Danenberg led the global operations, supply chain and service as COO for Degania Medical, a world leader for disposable catheters, cardiovascular catheters, and custom procedure trays, with 6 manufacturing plants and 3 logistics sites globally. Prior to that, Mr. Danenberg held the position of VP Operations for Taro Pharmaceuticals (NYSE: TARO), a multinational manufacturer of OTC and Rx oral solid dosage, semi-solid and liquid formulations. He led the operations of the Israeli and Canadian sites. Mr. Danenberg holds a B.Sc in Biotechnology and Food Engineering from the Technion – Israel Institute of Technology, and an MBA from Haifa University.

 

Mr. Ofer Halbreich 

VP Commercial & Corporate Development

Mr. Halbreich LLB, MBA, has 20 years of professional experience in diverse commercial negotiations and engagements, business development, strategic planning, M&As and global operations. Prior to joining MeMed’s team, Mr. Halbreich led the global operations activity of MediaMind Technologies Inc., and following its purchase by Digital Generation Inc. (Nasdaq: DGIT), led the global operations integration process of the companies. Prior to that, Mr. Halbreich was the COO of Neuronix Medical, an innovative medical device company in the field of Alzheimer’s disease treatment. Before that, Mr. Halbreich acted as VP of Business Development & Legal Counsel for Office Depot (Israel). Mr. Halbreich also served as a commercial lawyer for some of Israel’s most prominent law firms, handling large-scale commercial activities including M&A, joint ventures, licensing and investment agreements. Mr. Halbreich holds an LLB from the Hebrew University of Jerusalem and an MBA (Finance) from the Interdisciplinary Center in Herzliya.

Dr. Tanya Gottlieb

VP Scientific Affairs

Dr. Gottlieb has over 25 years of experience in academia and industry, specializing in building international collaborations and securing non-dilutive financing, including multi-million government contracts. Before joining MeMed, Dr. Gottlieb was Director of Business Development at BiondVax Pharmaceuticals Ltd (NASDAQ: BVXV), an innovative developer of a universal influenza vaccine. Dr. Gottlieb holds a BA in Natural Sciences and PhD in molecular biology from Cambridge University and an MBA from the Technion – Institute of Technology, Israel. Between completing her doctorate and entering biotech, Dr. Gottlieb was a postdoctoral fellow at the Weizmann Institute of Science, Israel and the Fred Hutchinson Cancer Research Center in Seattle, WA, USA. In 2004 Dr. Gottlieb founded Gottlieb Scientific Communications, which she ran for 10 years. Dr. Gottlieb is co-author of over 20 peer reviewed publications and the recipient of multiple awards, including the Royal Society (UK)-Israel Academy Postdoctoral Fellowship. 

Ms. Noga Salomon 

VP Engineering

Ms. Salomon has more than a decade experience in the medical device industry. Prior to joining MeMed’s team, Ms. Salomon was a part of the R&D systems group at Biosense Webster Inc, a J&J company that is a world leader in cardiac arrhythmia treatment. As a systems engineer, Ms. Salomon co-led the development of the ConfiDENSE™️ module, which later went on to win the J&J Hofmann award for innovation in 2016. Ms. Salomon has extensive experience in cardiac signal processing, systems engineering, cross-functional team management and medical device development processes. Ms. Salomon holds a B.Sc. in Electrical Engineering from the Technion-Israel Institute of Technology.  

Board of Directors

Mr. Terry is a social entrepreneur who has co-founded a dozen life science organizations in the last 20 years and has been called the godfather of applied genomics and personalized medicine. The organizations co-founded by Mr. Terry include innovative philanthropic, research, and commercial organizations based on the life sciences, applied technology, and social-network theory. In 2000, he co-founded Genomic Health, Inc. (NASDAQ: GHDX), a pioneering personalized medicine company. Mr. Terry has been involved in shepherding multiple biotechnology products through commercial development to clinical delivery all over the world. He has received many honors and awards in the business and scientific communities internationally. He has dedicated his career to advancing a patient-centered perspective in research, product development, and translational medicine. He is active internationally with strategic management and financing of stratified medicine companies for numerous clinical indications and technologies. 

Mr. Brandes is the founding and managing partner of Naschitz-Brandes, one of the leading law firms in Israel. Mr. Brandes has advised on some of Israel’s largest and most complex international commercial transactions. His clients include Israel’s leading public and private companies. Mr. Brandes is the chairman of the High-tech committee of the Israeli Bar, a member of the Board of Governors of Tel-Aviv University, as well as a member of the Board of Trustees and the Board of Directors of Tel-Aviv Museum of Art.

Mr. Patrick Zhang

Patrick Zhang is an investor at Horizons Ventures, where he primarily covers biotechnology, healthcare and fintech investments, and manages related portfolio companies for Horizons. He was trained as a chemical engineer and worked in a variety of organizations across industries including power utilities, financial services and investment management. Prior to Horizons, Patrick was an investment banker with Morgan Stanley providing financial advisory services on capital raising and cross-border M&A to his clients. Mr. Zhang received his BS degree in Chemical Engineering from UCLA and MBA from Columbia Business School.

Mr. Shmuel (Mooly) Eden

Mr. Eden is a former Senior Vice President at Intel Corporation, and President of Intel Israel. In this capacity, Mr. Eden led the PC Client Group, Intel’s largest product group with over $35 billion annual revenues in 2011, where he oversaw the platform planning, architecture, enabling, and marketing of Intel`s PC solutions for the desktop and mobile computing segments. In his 30 years at Intel, Mr. Eden held many management and technical positions in microprocessor design. Mr. Eden is considered one of the leaders of the mobile PC revolution. In 2010, Mr. Eden was ranked 26th on The Fast Company`s list of the world`s 100 most creative people. In 2012, Mr. Eden was named one of the world`s 10 most brilliant technological minds on the Fortune 500 list. On top of serving on Memed BOD, Mr Eden is the chairman of the Executive committee of the University of Haifa, and he consults and serves on the board of several startups.

Board of Advisors

Prof. Paul Feigin

Statistics  Advisor

Paul Feigin is Professor of Statistics and the Senior Executive VP of the Technion, Israel Institute of Technology. He is an authority on statistical design and analysis of genomic studies, and clinical studies. Prof. Feigin has served as a statistician regulatory consultant for many companies, working on clinical study protocol design and statistical analysis. He has extensive experience in strategic preparation for regulatory submission and communication with regulatory agencies and notified bodies. Prof. Feigin served as Dean of the Faculty of Industrial Engineering and Management at the Technion, as president of the Israel Statistical Association, and he is currently an elected fellow of the Institute of Mathematical Statistics and of the International Statistical Institute. Prof. Feigin published over 50 scientific papers and has been a visiting professor at world-class institutes including Berkeley, Cornell University, Stanford University and others. 

Dr. Louis Bont

Clinical Advisor

Dr. Bont, MD, PhD, is a Pediatrician Infectiologist at the University Medical Center Utrecht, The Netherlands. His research activities focus on viral respiratory tract infections, particularly RSV bronchiolitis. He leads the Utrecht RSV Research Group. Dr. Bont received several awards, including a European Society of Pediatric Infectious Diseases (ESPID) Fellowship Award. He has published 70 papers in peer-reviewed journals and is the chairman of the international Bronchiolitis Academy training program for pediatricians, the Global Expert Meeting on respiratory viruses (GEM) and the Training of Upcoming Leaders in Paediatric Sciences (TULIPS) in The Netherlands. He holds an ESPID membership. Dr. Bont earned his medical degree from the University of Amsterdam, The Netherlands and completed a residency in pediatrics at Victoria Hospital in Blackpool, United Kingdom; St. Antonius Hospital in Nieuwegein, The Netherlands; and Wilhelmina Children’s Hospital, University Medical Center in Utrecht, The Netherlands.

Prof. Itamar Shalit

Clinical Advisor

Prof. Shalit is an Associate Professor in Pediatrics, Sackler Faculty of Medicine, Tel-Aviv University and a world authority in Pediatric Infectious Diseases. Prof. Shalit served as the Director of the Infectious Diseases Unit and Director General of Schneider Children`s Hospital, tertiary care, referral pediatric center, for the entire state of Israel. He also served as the Director General of Carmel Hospital, the Chairman of the Israeli Society for Infectious Diseases, and as a member of the Scientific Advisory Boards of leading pharma and biotech companies including Bioline Rx, Teva Innovative Ventures, NasVax and Integra Ltd. Prof. Shalit is an active member of several national committees of the Israeli Ministry of Health among them the Advisory Board on Infectious Diseases and Immunization, Polio Eradication Committee, and the Epidemics Management Team. He was awarded the Certificate of Appreciation Declaration by the World Health Organization for outstanding efforts and success in poliomyelitis eradication in Israel. Prof. Shalit holds an MD from the Sackler School of Medicine, Tel-Aviv University and a MPA (Master in Public Administration) from the Kennedy School of Government at the Harvard University. He is the author of more than 90 peer reviewed scientific papers and currently serves as the CEO of the Galilee Biomedical Research Administration. 

Prof. Israel Potasman

Clinical Advisor

Prof. Potasman has been the Head of the Infectious Diseases Department at the Bnai-Zion Medical Center (BZMC), Haifa, for the past 22 years, and is a regional infectious disease consultant at Maccabi Health Services. He is a national authority on topics of travel medicine. Prof Potasman published over 120 scientific papers and reviews on a wide range of topics in infectious diseases and travel medicine. Prof. Potasman is a graduate of the Hebrew University, Hadassah Medical School, Jerusalem. He specialized in internal medicine at the BZMC, and in infectious diseases at Stanford University (laboratory of J.S. Remington). 

Prof. Zohar Yakhini

Scientific Advisor

Dr. Yakhini is a Professor of Computer Science at the Herzeliya Interdisciplinary Center and a Visiting Professor in the Computer Science Department at the Technion, Haifa. Dr Yakhini has been a Master Scientist at Agilent Laboratories until 2016, where he has led and mentored research and development work in the field of molecular measurement and bioinformatics. His group's current research mostly focuses on statistics, data analysis and machine learning techniques applied to molecular biology and to other domains. Dr. Yakhini has a publications h-index of 45 and is an inventor of 13 issued US patents.

Prof. Yoram Reiter

Scientific Advisor

Prof. Reiter is the former dean of the Faculty of Biology and the head of the Laboratory of Molecular Immunology at the Technion, Israel Institute of Technology. Prof. Reiter is a world leader in the isolation of human T-cell receptor-like (TCRL) molecules, with various applications in molecular immunology of cancer and infectious diseases. His work involves the development of novel immunotherapeutic approaches, as well as the study of molecular mechanisms in anti-tumor and anti-viral immunity. Prof. Reiter received his Ph.D. from the Department of Immunology at the Weizmann Institute of Science and subsequently spent five years at the National Cancer Institute (NCI) at the Laboratory of Molecular Biology headed by Dr. Ira Pastan, where he developed new approaches in antibody engineering. Prof. Reiter published over 100 scientific papers and reviews and holds 15 patents. He is the co-founder and CTO of Applied Immune Technology (AIT) Inc. and serves as an advisor to several pharmaceutical and biotechnology companies. 

Dr. Modi Segal

Dr. Segal is a seasoned businessman active in the high-tech and biotech industries and a philanthropist. He serves on the board of Governors of the Weizmann Institute of Science, was a senior executive of Texas Instruments and a co-founder and CTO of Libit Signal Processing, which was acquired by Texas Instruments in 1999 for $365 million. Dr. Segal holds a Ph.D. (with distinction) in electrical engineering from Tel Aviv University. 

Dr. Eli Opper

Dr. Opper brings over 45 years of experience in global R&D and business development in the high tech and biotech sectors. He is the former Chief Scientist of the Ministry of the Economy of Israel, a role he served from 2002 to 2010. He also served as the chairman of Eureka (2010-2011), a major pan-European R&D funding and coordination organization, and the chairman of BIRD foundation. Prior to that, Dr. Opper served as a venture partner at Giza Venture Capital from 2000 to 2002 and before that, he worked at Rafael for 27 years, where he held numerous roles including Chief of Staff and Corporate Vice President for R&D. Dr. Opper holds a B.Sc. and M.Sc. from the Technion, Israel Institute of Technology and Ph.D. in computer engineering from the University of Texas at Austin, TX. He published 14 papers in journals and conferences and over 50 internal papers at Rafael. 

Yahal Zilka 

Mr. Yahal Zilka brings many years of experience as an entrepreneur, mentor and executive. In addition to his knowledge of the communications and technology sectors, Mr. Zilka has worked closely with both the investment banking and venture capital communities. Mr. Zilka co-founded Magma Venture Partners and has positioned Magma as a major player in the New Media space. During his tenure as chairman and acting CEO of Phonetic Systems, a portfolio company of the Fund, Mr. Zilka led Magma’s first exit when Phonetic Systems was acquired by Nuance (NASDAQ: NUAN). Prior to Magma, Mr. Zilka served as CFO of VocalTec Communications from 1995 to 1999, where he was part of the team that pioneered VOIP and led the company from seed to its public offering on NASDAQ (NASDAQ: CALL). Mr. Zilka currently serves as Director on the boards of SightEra-Magisto, Valens Semiconductor and Indegy. Previously, Mr. Zilka was on the boards of Waze (acquired by Google, NASDAQ: GOOG), Onavo (acquired by Facebook, NASDAQ:FB), DesignArt Networks (acquired by Qualcomm, NASDAQ: QCOM) and Phonetic Systems (acquired by Nuance, NASDAQ: NUAN). Since 2009, Mr. Zilka has served as Chairman of the HTIA (now IATI) Annual Conference, Israel's most prestigious and comprehensive technology conference.